 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- bemnifosbuvir (AT-527) / Atea Pharma
Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2241;
P2
C223H was found to be the primary BEM RAV in GT- 1b and multiple substitutions at other NS5B regions were required to confer meaningful resistance, suggesting a very high barrier to resistance for BEM. BEM is currently being evaluated in combination with ruzasvir (RZR), a highly potent pan-genotypic NS5A inhibitor, in a Phase 2 clinical trial (NCT05904470).
- |||| GS-0938 / Gilead
Trial completion: QUANTUM: Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (clinicaltrials.gov) - Jun 11, 2013
P2, N=239, Completed, Sponsor: Gilead Sciences
BEM is currently being evaluated in combination with ruzasvir (RZR), a highly potent pan-genotypic NS5A inhibitor, in a Phase 2 clinical trial (NCT05904470). Active, not recruiting --> Completed
- ||| GS-0938 / Gilead
Enrollment change: QUANTUM: Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (clinicaltrials.gov) - Jun 6, 2012
P2, N=239, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed N=450 --> 239
- GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment change: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Jun 6, 2012
P1, N=24, Completed, Sponsor: Gilead Sciences
N=450 --> 239 N=48 --> 24
- | GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
Trial completion: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Jun 6, 2012
P1, N=24, Completed, Sponsor: Gilead Sciences
N=48 --> 24 Recruiting --> Completed
- | GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
New P1 trial: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Dec 20, 2011
P1, N=24, Completed, Sponsor: Gilead Sciences
- ||||| GS-0938 / Gilead
New P2 trial: QUANTUM: Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (clinicaltrials.gov) - Sep 13, 2011
P2, N=239, Completed, Sponsor: Gilead Sciences